|
US6150415A
(en)
*
|
1996-08-13 |
2000-11-21 |
The Regents Of The University Of California |
Epoxide hydrolase complexes and methods therewith
|
|
US8815951B2
(en)
*
|
1996-08-13 |
2014-08-26 |
The Regents Of The University Of California |
Inhibitors of epoxide hydrolases for the treatment of inflammation
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
ATE538794T1
(de)
|
1999-01-13 |
2012-01-15 |
Bayer Healthcare Llc |
Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
|
|
US7928239B2
(en)
|
1999-01-13 |
2011-04-19 |
Bayer Healthcare Llc |
Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
RU2319693C9
(ru)
|
1999-01-13 |
2008-08-20 |
Байер Копэрейшн |
Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
|
|
US6831099B1
(en)
*
|
1999-05-12 |
2004-12-14 |
Yale University |
Enzyme inhibition
|
|
ES2165768B1
(es)
|
1999-07-14 |
2003-04-01 |
Almirall Prodesfarma Sa |
Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
|
|
US6562563B1
(en)
*
|
1999-11-03 |
2003-05-13 |
Mitokor |
Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
WO2002082082A2
(en)
*
|
2001-04-09 |
2002-10-17 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorescence polarization assay
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
US6756210B2
(en)
*
|
2001-05-29 |
2004-06-29 |
The Regents Of The University Of California |
Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids
|
|
US6979733B2
(en)
*
|
2001-08-03 |
2005-12-27 |
Diversa Corporation |
Epoxide hydrolases, nucleic acids encoding them and methods of making and using them
|
|
US6943001B2
(en)
*
|
2001-08-03 |
2005-09-13 |
Diversa Corporation |
Epoxide hydrolases, nucleic acids encoding them and methods for making and using them
|
|
US20030139469A1
(en)
*
|
2002-01-23 |
2003-07-24 |
The Regents Of The University Of California |
Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation
|
|
SI1478358T1
(sl)
|
2002-02-11 |
2013-09-30 |
Bayer Healthcare Llc |
Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
|
|
SI1580188T1
(sl)
|
2002-02-11 |
2012-02-29 |
Bayer Healthcare Llc |
Aril sečnine kot kinazni inhibitorji
|
|
US20030216396A1
(en)
|
2002-02-11 |
2003-11-20 |
Bayer Corporation |
Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
|
|
GB0214342D0
(en)
*
|
2002-06-21 |
2002-07-31 |
Givaudan Sa |
Insect repellents
|
|
JP4515911B2
(ja)
|
2002-10-07 |
2010-08-04 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
アナンダミド加水分解の遮断による不安の調節
|
|
US7557129B2
(en)
|
2003-02-28 |
2009-07-07 |
Bayer Healthcare Llc |
Cyanopyridine derivatives useful in the treatment of cancer and other disorders
|
|
US20050164951A1
(en)
*
|
2003-04-03 |
2005-07-28 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
|
CA2520763A1
(en)
*
|
2003-04-03 |
2004-10-21 |
The Regents Of The University Of California |
Improved inhibitors for the soluble epoxide hydrolase
|
|
EP1626714B1
(en)
|
2003-05-20 |
2007-07-04 |
Bayer Pharmaceuticals Corporation |
Diaryl ureas for diseases mediated by pdgfr
|
|
EP1663978B1
(en)
|
2003-07-23 |
2007-11-28 |
Bayer Pharmaceuticals Corporation |
Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
|
|
CA2559665A1
(en)
|
2004-03-16 |
2005-09-29 |
The Regents Of The University Of California |
Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
|
|
ES2257152B1
(es)
*
|
2004-05-31 |
2007-07-01 |
Laboratorios Almirall S.A. |
Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos.
|
|
US7662910B2
(en)
|
2004-10-20 |
2010-02-16 |
The Regents Of The University Of California |
Inhibitors for the soluble epoxide hydrolase
|
|
JP2008540424A
(ja)
*
|
2005-05-06 |
2008-11-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ｓＥＨインヒビターとしてのアシルヒドラゾンの使用方法
|
|
EP1885697A2
(en)
*
|
2005-05-06 |
2008-02-13 |
Boehringer Ingelheim International Gmbh |
Soluble epoxide hydrolase inhibitors and methods of using same
|
|
US9119837B2
(en)
*
|
2005-08-19 |
2015-09-01 |
The Regents Of The University Of California |
Use of sEH inhibitors as analgesics
|
|
CA2622754A1
(en)
*
|
2005-10-07 |
2007-04-19 |
Boehringer Ingelheim International Gmbh |
N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors
|
|
KR101434522B1
(ko)
|
2005-11-09 |
2014-08-26 |
오닉스 세라퓨틱스, 인크. |
효소 저해를 위한 화합물
|
|
JP2009523134A
(ja)
*
|
2006-01-13 |
2009-06-18 |
マクギル ユニバーシティー |
抗うつ作用ならびに睡眠誘発性を有する新規なメラトニンリガンド
|
|
WO2007106705A1
(en)
*
|
2006-03-10 |
2007-09-20 |
Boehringer Ingelheim International Gmbh |
Soluble epoxide hydrolase inhibitors and methods of using same
|
|
AR059826A1
(es)
*
|
2006-03-13 |
2008-04-30 |
Univ California |
Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
|
|
RU2450016C2
(ru)
|
2006-06-19 |
2012-05-10 |
Протеоликс, Инк. |
Пептидные эпоксикетоны для ингибирования протеасомы
|
|
WO2008073130A1
(en)
*
|
2006-12-15 |
2008-06-19 |
Regents Of The University Of California |
Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by pbr, cb2, and nk2 receptors
|
|
EP2091542A1
(en)
*
|
2006-12-18 |
2009-08-26 |
F. Hoffmann-Roche AG |
Novel use of inhibitors of soluble epoxide hydrolase
|
|
EP2178534A4
(en)
*
|
2007-07-17 |
2011-03-30 |
Merck Sharp & Dohme |
SOLUBLE EPOXYHYDROLASE HEMMER, COMPOSITIONS WITH SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
|
|
WO2009020960A1
(en)
|
2007-08-06 |
2009-02-12 |
The Regents Of The University Of California |
Preparation of novel 1,3-substituted ureas as inhibitors of soluble epoxide hydrolase
|
|
SI2207791T2
(sl)
*
|
2007-10-04 |
2019-09-30 |
Onyx Therapeutics, Inc. |
Kristalinični peptidepoksiketonski proteazni inhibitorji in sinteza aminokislinskih ketoepoksidov
|
|
EP2259680A4
(en)
*
|
2008-03-04 |
2012-01-25 |
Merck Sharp & Dohme |
SOLUBLE EPOXYHYDROLASE INHIBITORS, COMPOSITIONS COMPRISING SUCH COMPOUNDS AND TREATMENT METHODS THEREWITH
|
|
EP2100598A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2100599A1
(en)
|
2008-03-13 |
2009-09-16 |
Laboratorios Almirall, S.A. |
Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease
|
|
EP2796134B1
(en)
|
2008-10-21 |
2016-12-07 |
Onyx Therapeutics, Inc. |
Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
|
|
WO2010096722A1
(en)
|
2009-02-20 |
2010-08-26 |
Takeda Pharmaceutical Company Limited |
3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors
|
|
AR075899A1
(es)
|
2009-03-20 |
2011-05-04 |
Onyx Therapeutics Inc |
Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
|
|
EP2498793B1
(en)
|
2009-11-13 |
2019-07-10 |
Onyx Therapeutics, Inc. |
Oprozomib for use in metastasis suppression
|
|
EP2528604B1
(en)
|
2010-01-29 |
2017-11-22 |
The Regents of the University of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
AU2011223795B2
(en)
|
2010-03-01 |
2015-11-05 |
Onyx Therapeutics, Inc. |
Compounds for immunoproteasome inhibition
|
|
KR20130094185A
(ko)
|
2010-04-07 |
2013-08-23 |
오닉스 세라퓨틱스, 인크. |
결정성 펩티드 에폭시케톤 면역프로테아좀 저해제
|
|
EP2389922A1
(en)
|
2010-05-25 |
2011-11-30 |
Symrise AG |
Cyclohexyl carbamate compounds as anti-ageing actives
|
|
EP2675274B1
(en)
|
2011-02-14 |
2017-05-03 |
The Regents of The University of California |
SORAFENIB DERIVATIVES AS sEH INHIBITORS
|
|
EP2510928A1
(en)
|
2011-04-15 |
2012-10-17 |
Almirall, S.A. |
Aclidinium for use in improving the quality of sleep in respiratory patients
|
|
WO2013116690A1
(en)
|
2012-02-01 |
2013-08-08 |
The Regents Of The University Of California |
Acyl piperidine inhibitors of soluble epoxide hydrolase
|
|
US10383835B2
(en)
|
2012-03-14 |
2019-08-20 |
The Regents Of The University Of California |
Treatment of inflammatory disorders in non-human mammals
|
|
US20140105921A1
(en)
|
2012-07-09 |
2014-04-17 |
Onyx Therapeutics, Inc. |
Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
|
|
WO2016133788A1
(en)
|
2015-02-20 |
2016-08-25 |
The Regents Of The University Of California |
Methods of inhibiting pain
|
|
WO2017202957A1
(en)
|
2016-05-25 |
2017-11-30 |
Johann Wolfgang Goethe-Universität Frankfurt am Main |
Treatment and diagnosis of non-proliferative diabetic retinopathy
|
|
US20210378995A1
(en)
|
2018-10-10 |
2021-12-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction
|
|
CN113302298B
(zh)
|
2018-11-09 |
2025-02-25 |
银杏生物制品公司 |
罗汉果甙的生物合成
|